Staar Surgical (NSDQ:STAA) posted fourth-quarter results this week that beat the earnings consensus on Wall Street and missed revenue estimates.
The Lake Forest, California-based company reported profits of $4.9 million, or 10¢ per share, on sales of $59 million for the three months ended Dec. 31, 2020, for a bottom-line gain of 47.9% on sales growth of 28.27% compared with Q4 2020.
Adjusted to exclude one-time items, earnings per share were 19¢, 3¢ ahead of The Street, where analysts were looking for sales of $59.21 million.
“Our fiscal 2021 results reflect record levels of sales, profit and growth achievement for Staar, driven by continued accelerating demand for our implantable Collamer lenses,” president and CEO Caren Mason said in a news release.
Staar Surgical did not provide a financial outlook for fiscal year 2022.
Shares in STAA were up 13.91% to $71.75 apiece in afternoon trading.